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We read with great interest the article by Fourrier and 
colleagues [1], who investigated functional markers to 
predict the need for prolonged mechanical ventilation 
(MV) in patients with Guillain-Barré syndrome (GBS) 
and acute respiratory failure. Th  e study was well con-
ducted, but we are concerned about the study design and 
the confounding factors.
Firstly, we want to know why the authors chose 15 days 
as a cutoﬀ   point of MV duration. As mentioned in the 
article, tracheotomy is indicated in GBS patients when a 
long duration of MV is expected [1]. Although the 
optimal time for performing tracheotomy is not well 
known, it is usually considered after 3 weeks of prolonged 
MV [2]. In this context, we are eager to know whether the 
lack of foot ﬂ   exion ability was associated with a MV 
length of more than 21 days. If so, it might be used as a 
predictor for tracheotomy. Secondly, the authors seem to 
equate MV with endotracheal MV in their research. We 
therefore want to ask whether the authors used non-
invasive mask MV in patients at the very early stages of 
respiratory failure. Th  irdly, delay between disease onset 
and admission or initiation of immunotherapy seems to 
diﬀ  er among GBS patients. Th   is may confound the data 
analysis since the predictive values of foot ﬂ  exion ability 
may diﬀ  er between patients beginning to receive immuno-
therapy from the recovery stage and from the acute stage 
[3]. Lastly, although immunotherapy can change the 
natural course of GBS, other factors may act in an 
opposite way. Complicated infections and electrolyte 
disorders [4] may aggravate respiratory muscle weakness 
and lead to prolonged use of MV.
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In our study, we mainly considered the 15 days cutoﬀ   
point on a ‘pragmatic’ basis. In GBS patients, immuno-
therapy needs to be given for 5 to 7 days and the ﬁ  rst 
signs of improvement are expected in the following 7 days. 
If at the end of immunotherapy a marker may predict a 
lack of improvement, waiting more time will delay 
tracheo  tomy needlessly and may result in a higher risk of 
complications. In agreement, presently published recom-
mendations and experts’ opinions mostly consider 10 to 
15 days as the optimal delay for performing tracheotomy 
[5,6]. Moreover, tracheotomy after 21 days might be 
associated with longer ICU stay and higher mortality [7].
Non-invasive mechanical ventilation (NIMV) was not 
used in our severe GBS patients. Th  ey are usually 
considered poor candidates for NIMV, being at very high 
risk of sudden respiratory arrest, aspiration, atelectasis, 
and cardiac troubles. Due to facial paresis, severe air 
leaks may limit eﬃ   cacy and tolerance. Prolonged NIMV 
may provoke severe skin lesions and induce high care 
loads and monitoring needs [8].
None of our patients was treated from the recovery 
phase. Th  e median delay between onset of the disease 
and ICU admission was 6 days, and all patients were 
given immunotherapy in the ICU soon after admission.
Finally, we completely agree that infection and electro-
lyte disorders should be aggressively treated. Th  is is 
surely of great matter and refers to standard critical care. 
Th   e best way to improve neurological status remains to 
shorten the course of the disease by early immunotherapy.
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